SCHEMBL5083186

SCHEMBL5083186

O=C1Nc2ccc(OC(F)(F)F)cc2/C1=C/c1cc(Br)c(O)c(Br)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.73
RAF1 P04049 11/20 0.64
MAP1LC3B Q9GZQ8 3/20 0.64
PSEN1 P49768 1/20 0.64
PSEN2 P49810 1/20 0.64
APH1B Q8WW43 1/20 0.64
NCSTN Q92542 1/20 0.64
APH1A Q96BI3 1/20 0.64
PSENEN Q9NZ42 1/20 0.64
EGFR P00533 1/20 0.64
NTRK1 P04629 1/20 0.64
ARAF P10398 1/20 0.64
PIM1 P11309 1/20 0.64
BRAF P15056 1/20 0.64
CSNK2A1 P68400 1/20 0.64
PIM3 Q86V86 1/20 0.64
SIRT2 Q8IXJ6 1/20 0.64
SIRT1 Q96EB6 1/20 0.64
MYOC Q99972 1/20 0.64
DYRK4 Q9NR20 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1395239 1.00 LRRK2 (0.73) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL1394503 0.91 LRRK2 (0.70) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL1394501 0.91 LRRK2 (0.70) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL1395237 0.88 LRRK2 (0.61) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL1395238 0.88 LRRK2 (0.61) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL1394515 0.86 RAF1 (0.60) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL5086182 0.86 RET (0.60) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL4728586 0.86 RAF1 (0.60) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL1394877 0.86 RET (0.60) LRRK2RAF1MAP1LC3BPSEN1PSEN2
SCHEMBL3753224 0.81 RAF1 (0.73) LRRK2RAF1MAP1LC3BPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
EP-1003721-B1 BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES GLAXO GROUP LTD (GB) 2006-11-02 EP disclosed
US-6268391-B1 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases GLAXO WELLCOME INC. 2001-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN LRRK2 408/4885RAF1 4132/4885MAP1LC3B 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.